Beyondspring Inc
BYSI2.350USD
+0.480+25.67%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
94.76MMarket Cap
LossP/E TTM
More Details of Beyondspring Inc Company
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Beyondspring Inc Info
Ticker SymbolBYSI
Company nameBeyondspring Inc
IPO dateMar 09, 2017
CEOHuang (Lan)
Number of employees40
Security typeOrdinary Share
Fiscal year-endMar 09
Address100 Campus Drive, West Side, 4Th Floor
CityFLORHAM PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07932
Phone16465284184
Websitehttps://www.beyondspringpharma.com/en/
Ticker SymbolBYSI
IPO dateMar 09, 2017
CEOHuang (Lan)
Company Executives of Beyondspring Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Mr. Matthew Kirkby
Mr. Matthew Kirkby
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Huang (Lan)
10.17%
Decheng Capital LLC
9.85%
Jia (Linqing)
4.26%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
1.27%
Other
73.14%
Shareholders
Shareholders
Proportion
Huang (Lan)
10.17%
Decheng Capital LLC
9.85%
Jia (Linqing)
4.26%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
1.27%
Other
73.14%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.68%
Venture Capital
9.85%
Investment Advisor
2.68%
Investment Advisor/Hedge Fund
1.16%
Hedge Fund
0.03%
Research Firm
0.03%
Other
71.56%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
47
5.77M
16.11%
-154.71K
2025Q3
53
5.93M
17.53%
+5.28K
2025Q2
53
6.03M
15.88%
+744.23K
2025Q1
54
5.29M
16.11%
-1.21M
2024Q4
62
5.27M
16.28%
-285.43K
2024Q3
64
5.56M
17.50%
-221.76K
2024Q2
76
5.78M
16.75%
-119.18K
2024Q1
120
5.90M
18.41%
-1.29M
2023Q4
135
5.48M
18.65%
-172.81K
2023Q3
161
5.67M
20.72%
-51.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Huang (Lan)
4.26M
10.57%
--
--
Feb 28, 2025
Decheng Capital LLC
4.36M
10.8%
-67.53K
-1.53%
Sep 30, 2025
Jia (Linqing)
1.78M
4.43%
+4.00
+0.00%
Feb 28, 2025
The Vanguard Group, Inc.
523.70K
1.3%
+523.70K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
529.90K
1.31%
+413.93K
+356.94%
Jun 30, 2025
Geode Capital Management, L.L.C.
256.21K
0.64%
+231.84K
+951.43%
Jun 30, 2025
BlackRock Financial Management, Inc.
90.54K
0.22%
--
--
Jun 30, 2025
Northern Trust Investments, Inc.
16.31K
0.04%
-396.00
-2.37%
Jun 30, 2025
Fabbio (Patrick)
53.86K
0.13%
+29.27K
+119.03%
Feb 28, 2025
Majeti (Jiangwen)
50.91K
0.13%
--
--
Feb 28, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Beyondspring Inc?
The top five shareholders of Beyondspring Inc are:
Huang (Lan) holds 4.26M shares, accounting for 10.57% of the total shares.
Decheng Capital LLC holds 4.36M shares, accounting for 10.80% of the total shares.
Jia (Linqing) holds 1.78M shares, accounting for 4.43% of the total shares.
The Vanguard Group, Inc. holds 523.70K shares, accounting for 1.30% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 529.90K shares, accounting for 1.31% of the total shares.
Huang (Lan) holds 4.26M shares, accounting for 10.57% of the total shares.
Decheng Capital LLC holds 4.36M shares, accounting for 10.80% of the total shares.
Jia (Linqing) holds 1.78M shares, accounting for 4.43% of the total shares.
The Vanguard Group, Inc. holds 523.70K shares, accounting for 1.30% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 529.90K shares, accounting for 1.31% of the total shares.
What are the top three shareholder types of Beyondspring Inc?
The top three shareholder types of Beyondspring Inc are:
Huang (Lan)
Decheng Capital LLC
Jia (Linqing)
Huang (Lan)
Decheng Capital LLC
Jia (Linqing)
How many institutions hold shares of Beyondspring Inc (BYSI)?
As of 2025Q4, 47 institutions hold shares of Beyondspring Inc, with a combined market value of approximately 5.77M, accounting for 16.11% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.42%.
What is the biggest source of revenue for Beyondspring Inc?
In --, the -- business generated the highest revenue for Beyondspring Inc, amounting to -- and accounting for --% of total revenue.
